Our History

Founded in 2012 as a spin-off from Dalhousie University in Halifax, Nova Scotia, we are now beginning to study our lead products in clinical human trials 

ABK Over the Years


ABK Biomedical Founded

Founded at Dalhousie University in 2012, The Three Founders; Interventional Radiologist Robert Abraham, MD, and Material Scientists, Dr’s Daniel Boyd, and Sharon Kehoe, engineered and patented a new platform technology based on “x-ray visible” glass microspheres.



Production of proprietary glass microspheres began in Halifax, Nova Scotia.

Delivery System

1st Generation delivery system was developed for bland microspheres.


Focus on Yttrium90 (Y90)

ABK’s proprietary glass microspheres were redesigned with a focus on Y90 radioembolization.

New Management Team

An experienced management team was hired under new CEO and President Mike Mangano.


Raised $30M USD in Series B Funding

The largest medical device venture capital raise in Atlantic Canada is used to further develop Eye90 microspheres®, and Easi-Vue™ embolic microspheres.

Multi-year Strategic Partnership with MURR®

The Missouri University Research Reactor Center is the primary irradiation partner for ABK’s radioembolization products.

Y90 microsphere production


Eye90 microspheres®

Finalized design and completed pre-clinical testing for Eye90 microspheres® technology.

Accelerated Manufacturing

Commissioned two new manufacturing and cleanroom facilities to accelerate device operations.


Y90 microsphere production


Clinical Transition

ABK Biomedical transitioned from a pre-clinical to a clinical-stage company with the initiation of the First-in-Human clinical study with Eye90 microspheres® in November 2021.


Bland embolization with easi-vue embolic microspheres


Regulatory Execution

ABK Biomedical announced the first patient treated with Eye90 microspheres® in early 2022 and achieved 510(k) clearance from the FDA for Easi-Vue™ embolic microspheres in September 2022.


Eye90 microspheres logo


FDA IDE Approval

ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma in 2023.



ABK Biomedical Recognition

Interventional Oncology related Journals, Conferences and Societies Recognize ABK Biomedical’s Breakthrough Technology Development


The ABK Biomedical Team

We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.

ABK Biomedical is an equal opportunity employer offering competitive compensation packages.

ABK's Business Partners

ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.

Research Partners

Development Partners

ABK Biomedical is ISO Certified

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3

T. 902.442.4009


Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.

Copyright 2022 - All International Rights Reserved